Skip to main content
SpringerLink
Log in

Pai-1 Gene Variants and COC Use Are Associated with Stroke Risk: A Case-Control Study in the Han Chinese Women

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Genetic variants of plasminogen activator inhibitor type 1 (PAI-1) gene have been suggested to influence the PAI-1 transcription activity and PAI-1 levels as well as might be involved in the pathophysiology of stroke. The aims of this study are to investigate whether the polymorphisms at the PAI-1 gene are associated with the risk of stroke and to explore the combined effects of PAI-1 variants and combined oral contraceptive (COC) use for stroke risk. We conducted a nested case-control study using 453 first-ever female stroke cases and 919 age- and region-matched controls that were recruited from our prospective surveillance cohort. SNP rs1799889 was genotyped by allele-specific polymerase chain reaction (PCR), and SNPs rs7242 and rs2227631 were detected by the TaqMan SNP genotyping assay. We identified that rs1799889 5G allele conferred a protective effect against ischemic stroke while 4G allele conferred an increased risk of ischemic stroke. But we failed to suggest associations of rs7242 and rs2227631. COC users had a 1.31-fold (OR = 1.31, 95 % CI = 1.01–1.71) increased risk of stroke compared with the non-users. Furthermore, COC users with rs1799889 4G5G/5G5G genotype had a decreased risk of ischemic stroke (OR = 0.53, 95 % CI = 0.34–0.83). Moreover, haplotype G-5G-T was associated with an increased risk of overall stroke (OR = 1.28, 95 % CI = 1.01–1.62). In contrast, haplotype A-4G-G and haplotype G-5G-T were slightly associated with the protection from ischemic stroke (OR = 0.61, 95 % CI = 0.46–0.82; OR = 0.61, 95 % CI = 0.44–0.85, respectively). The study assessed the associations of three PAI-1 SNPs and also suggested combined effects of these PAI-1 gene variants and COC use on stroke risk in the Han Chinese women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1

Similar content being viewed by others

References

  • Adamski MG, Turaj W, Slowik A, Wloch-Kopec D, Wolkow P, Szczudlik A (2009) A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand 120(2):94–100

    Article  CAS  PubMed  Google Scholar 

  • Algra AM, Klijn CJ, Helmerhorst FM, Algra A, Rinkel GJ (2012) Female risk factors for subarachnoid hemorrhage: a systematic review. Neurology 79(12):1230–1236

    Article  PubMed  Google Scholar 

  • Attia J, Thakkinstian A, Wang Y, Lincz L, Parsons M, Sturm J, McGettigan P, Scott R, Meldrum C, Levi C (2007) The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc Dis 16(4):173–179

    Article  PubMed  Google Scholar 

  • Babu MS, Prabha TS, Kaul S, Al-Hazzani A, Shafi G, Roy S, Balakrishna N, Jyothy A, Munshi A (2012) Association of genetic variants of fibrinolytic system with stroke and stroke subtypes. Gene 495(1):76–80

    Article  CAS  PubMed  Google Scholar 

  • Balcerzyk A, Żak I, Emich-Widera E, Kopyta I, Iwanicki T, Pilarska E, Pienczk-Ręcławowicz K, Kaciński M, Wendorff J, Połatyńska K (2011) The plasminogen activator inhibitor-1 gene polymorphism in determining the risk of pediatric ischemic stroke—case control and family-based study. Neuropediatrics 42(2):67–70

    Article  CAS  PubMed  Google Scholar 

  • Boncoraglio GB, Bodini A, Brambilla C, Carriero MR, Ciusani E, Parati EA (2006) An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke. Cerebrovasc Dis 22(2–3):191–195

    Article  CAS  PubMed  Google Scholar 

  • Casslén B, Urano S, Ny T (1992) Progesterone regulation of plasminogen activator inhibitor 1 (PAI-1) antigen and mRNA levels in human endometrial stromal cells. Thromb Res 66(1):75–87

    Article  PubMed  Google Scholar 

  • Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ (1997) Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 77(4):730–734

    CAS  PubMed  Google Scholar 

  • de Paula SA, Ribeiro DD, Domingueti CP, Dos Santos MS, Gadelha T, Dusse LM, das Graças Carvalho M, Fernandes AP (2011) Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke. Mol Biol Rep 38(8):5355–5360

    Article  Google Scholar 

  • Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93(4):631–640

    CAS  PubMed  Google Scholar 

  • Dinger J, Assmann A, Möhner S, Minh TD (2010) Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 36(3):123–129

    Article  PubMed  Google Scholar 

  • Fernandez-Cadenas I, Del Rio-Espinola A, Rubiera M, Mendioroz M, Domingues-Montanari S, Cuadrado E, Hernandez-Guillamon M, Rosell A, Ribo M, Alvarez-Sabin J, Molina CA, Montaner J (2010) PAI-1 4G/5G polymorphism is associated with brain vessel reocclusion after successful fibrinolytic therapy in ischemic stroke patients. Int J Neurosci 120(4):245–251

    Article  CAS  PubMed  Google Scholar 

  • Festa A, D’Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM (2003) Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 107:2422–2427

    Article  CAS  PubMed  Google Scholar 

  • Follo M, Ginsburg D (1989) Structure and expression of the human gene encoding plasminogen activator inhibitor, PAI-1. Gene 84(2):447–453

    Article  CAS  PubMed  Google Scholar 

  • Hamsten A, Eriksson P (1995) Fibrinolysis and atherosclerosis. Baillieres Clin Haematol 8(2):345–363

    Article  CAS  PubMed  Google Scholar 

  • Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP (2002) The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9(2):131–137

    Article  PubMed  Google Scholar 

  • Huezo CM (1998) Current reversible contraceptive methods: a global perspective. Int J Gynaecol Obstet 62(Suppl 1):S3–15

    Article  PubMed  Google Scholar 

  • Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G (2000) Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31(1):26–32

    Article  CAS  PubMed  Google Scholar 

  • Li Y, Zhou L, Coulter D, Gao E, Sun Z, Liu Y, Wang X (2006) Prospective cohort study of the association between use of low dose oral contraceptives and stroke in Chinese women. Pharmacoepidemiol Drug Saf 15:726–734

    Article  CAS  PubMed  Google Scholar 

  • Li Y, Chen F, Zhou L, Coulter D, Chen C, Sun Z, Chen J, Pan H, Wu Y, Zhou J, Ba L, Zhao J, Shen H (2010) COC use, ACE/AGT gene polymorphisms, and risk of stroke. Pharmacogenet Genomics 20(5):298–306

    Article  CAS  PubMed  Google Scholar 

  • Liu L, Wang D, Wong KS, Wang Y (2011) Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 42(12):3651–3654

    Article  PubMed  Google Scholar 

  • Mansfield MW, Stickland MH, Grant PJ (1995) Plasminogen activator inhibitor-1 (PAI-1) promotor polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74(4):1032–1034

    CAS  PubMed  Google Scholar 

  • Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G, Juhan-Vague I (1999) PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 19(5):1361–1365

    Article  CAS  PubMed  Google Scholar 

  • Morange PE, Saut N, Alessi MC, Yudkin JS, Margaglione M, Di Minno G, Hamsten A, Humphries SE, Tregouet DA, Juhan-Vague I (2007) Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 27(10):2250–2257

    Article  CAS  PubMed  Google Scholar 

  • Rantanen K, Tatlisumak T (2013) Stroke in women—oral contraception, pregnancy, and hormone replacement therapy. Curr Vasc Pharmacol 11(1):58–73

    Article  CAS  PubMed  Google Scholar 

  • Roest M, Banga JD (2003) Editorial comment—genetic make-up for increased PAI-1 expression protects against stroke. Stroke 34(12):2828–2829

    Article  PubMed  Google Scholar 

  • Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY (2007) Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study. J Stroke Cerebrovasc Dis 16(4):153–159

    Article  PubMed  Google Scholar 

  • Sirgo G, Pérez-Vela JL, Morales P, Del Rey M, Vendrell J, Gutierrez C, Rello J (2006) Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery. Intensive Care Med 32(5):668–675

    Article  CAS  PubMed  Google Scholar 

  • Su S, Chen S, Zhao J, Huang J, Wang X, Chen R, Gu D (2006) Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease. Arterioscler Thromb Vasc Biol 26(4):948–954

    Article  CAS  PubMed  Google Scholar 

  • van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, Büller HR, Meijer K. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood, 2011, 25, 118 (8):2055–2061.

  • Vergouwen MD, Frijns CJ, Roos YB, Rinkel GJ, Baas F, Vermeulen M (2004) Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 35(6):1280–1283

    Article  CAS  PubMed  Google Scholar 

  • Wang C, Li Y, Li H, Sun T, Jin G, Sun Z, Zhou J, Ba L, Huang Z, Bai J (2012) Increased risk of stroke in oral contraceptive users carried replicated genetic variants: a population-based case-control study in China. Hum Genet 131(8):1337–1344

    Article  CAS  PubMed  Google Scholar 

  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996a) Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348:505–510

    Article  Google Scholar 

  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1996b) Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348:498–505

    Article  Google Scholar 

  • Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K (2005) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36(8):1661–1665

    Article  CAS  PubMed  Google Scholar 

  • Xu X, Li J, Sheng W, Liu L (2008) Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 26(1):48–62

    Article  PubMed  Google Scholar 

  • Zakharova MY, Meyer RM, Brandy KR, Datta YH, Joseph MS, Schreiner PJ, Rao GH, Divani AA (2011) Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use. Clin Appl Thromb Hemost 17(4):323–331

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by National Natural Science Foundation of China (No. 30972542), National 11th Five Year-Plan Key Projects (2006BAI15B07) and Jiangsu Province Science and Technology Agency Program (BM2012062). Our sincere thanks go to Zhiming Sun, Jian Zhou, Lei Ba, Yulin Wu, Xiangjun Zhu, and Ying Chen (NPFPC Contraceptives Adverse Reaction Monitoring Center, Jiangsu Institute of Planned Parenthood Research, China) for their help in study working and data collecting.

Conflict of Interest

All authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Epidemiology & Biostatistics, School of Public Health, Nanjing Medical University, 818 East Tianyuan Road, Jiangning District, Nanjing, 211166, Jiangsu, China

    Xiaoping Huang, Ying Li & Zhenlin Xu

  2. Jiangsu Institute of Planned Parenthood Research, 277 Feng Huang Xi Jie, Nanjing, 210036, Jiangsu, China

    Ying Li

  3. Suzhou Center for Disease Prevention and Control, 72 Sanxiang Road, Suzhou, 215000, China

    Zhizheng Huang

  4. Department of Occupational Medicine and Environmental Toxicology, Nantong University, 9 Se Yuan Road, Nantong, 226000, China

    Chun Wang

Authors
  1. Xiaoping Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhizheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhenlin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ying Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, X., Li, Y., Huang, Z. et al. Pai-1 Gene Variants and COC Use Are Associated with Stroke Risk: A Case-Control Study in the Han Chinese Women. J Mol Neurosci 54, 803–810 (2014). https://doi.org/10.1007/s12031-014-0418-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-014-0418-0

Keywords

Search

Navigation